Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.
Pear Therapeutics, Inc.’s reSET and reSET-O prescription digital therapeutics (PDTs) for the treatment of substance use disorder and opioid use disorder will be covered under Medicaid in Massachusetts.
According to Pear, this is first state Medicaid program decision to cover prescription digital therapeutics. MassHealth, the state’s agency for...
Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.
